Placebo News and Research

RSS

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

Understanding neurobiological mechanisms of empathy

In a study with more than 100 participants, Claus Lamm and his interdisciplinary team used an innovative experimental trick, the so-called placebo analgesia effect, to close an explanatory gap in the understanding of the neurobiological mechanisms of empathy.

30 Sep 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

Spiolto Respimat shown to be superior first line therapy over LABA/ICS for COPD

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015

29 Sep 2015

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Teva Pharmaceutical Industries Ltd., has presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75 percent versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS).

28 Sep 2015

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.

28 Sep 2015

Two-drug combination relieves depression in older adults

More than half of older adults with clinical depression don't get better when treated with an antidepressant. But results from a multicenter clinical trial that included Washington University School of Medicine in St. Louis indicates that adding a second drug — an antipsychotic medication — to the treatment regimen helps many of those patients.

28 Sep 2015

Study may lead to new insights on use of aspirin in GI cancer

Aspirin improves survival in patients with tumours situated throughout the gastrointestinal (GI) tract, results from a large study in The Netherlands show. This is the first time that survival data from patients with tumours in different GI locations have been analysed at the same time; previously, only one type of cancer, usually colorectal, was studied.

28 Sep 2015

SLU participates in Phase III clinical trial to treat early-onset preeclampsia

Saint Louis University is participating in a Phase III clinical trial for a drug to treat early-onset preeclampsia in pregnant women that could increase the length of pregnancy, resulting in improved fetal outcomes and reduced infant mortality.

26 Sep 2015

University of Oslo researchers examine treatment methods for tennis elbow

The two most common treatments for tennis elbow are physiotherapy and cortisone injections. It is unclear which of these gives the best result, and diagnosis can be problematic for general practitioners. Now researchers at the University of Oslo have taken a closer look at the treatment methods.

25 Sep 2015

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

AbbVie, a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors.

25 Sep 2015

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).

24 Sep 2015

Study explores effectiveness of frontline treatments for couples with unexplained infertility

A breast cancer drug with promise for improving the chance that couples with unexplained infertility can have a baby without increasing their risk of multiple births apparently does not deliver, according to a comparative study.

24 Sep 2015

Dextromethorphan–quinidine promising for agitation in Alzheimer’s patients

The combination of dextromethorphan hydrobromide and quinidine sulphate shows promising efficacy against agitation in a phase 2 trial in patients with Alzheimer’s disease.

23 Sep 2015

Radboud university medical center reveals how BCG vaccine works against tuberculosis

Not only the acquired immune system but also the innate immune system has a memory. And the BCG vaccine against tuberculosis can stimulate this memory. After a BCG vaccination the innate immune system responds better to a wide range of other infections. Mihai Netea and colleagues from Radboud university medical center discovered and described how that works. They think that the old vaccine could be useful for specific target groups, such as the elderly.

23 Sep 2015

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

$Bisphosphonate drugs linked to greater risk of atypical hip fractures$

Bisphosphonate drugs linked to greater risk of atypical hip fractures

The use of bisphosphonates, a group of drugs used to prevent hip breakages in women with osteoporosis, is associated with an increased risk of atypical fractures in this joint, understood as those that occur in less frequent locations.

22 Sep 2015

New Medicare payment model reduces use of low-value services

In the first large-scale study to assess the effects of the Affordable Care Act's reforms to physician and hospital payments on the use of wasteful health care services, researchers have found that a new Medicare payment model reduced the number of times patients received services providing little or no health benefit.

22 Sep 2015

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

Researchers from Brigham and Women's Hospital and Dana-Farber Cancer Institute have received a $10 million Breakthrough Award from the Department of Defense's Office of the Congressionally Directed Medical Research Program to test whether aspirin helps women with breast cancer avoid recurrence and live longer.

22 Sep 2015

Higher doses of hydrocortisone not linked to neurodevelopmental impairments in low birth weight infants

Hydrocortisone is one of the 15 most frequently prescribed medications in extremely low birth weight (?1000 g) infants in the newborn intensive care unit (NICU).

21 Sep 2015

Placebo News and Research

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

Understanding neurobiological mechanisms of empathy

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Spiolto Respimat shown to be superior first line therapy over LABA/ICS for COPD

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Two-drug combination relieves depression in older adults

Study may lead to new insights on use of aspirin in GI cancer

SLU participates in Phase III clinical trial to treat early-onset preeclampsia

University of Oslo researchers examine treatment methods for tennis elbow

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Study explores effectiveness of frontline treatments for couples with unexplained infertility

Dextromethorphan–quinidine promising for agitation in Alzheimer’s patients

Radboud university medical center reveals how BCG vaccine works against tuberculosis

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Bisphosphonate drugs linked to greater risk of atypical hip fractures

New Medicare payment model reduces use of low-value services

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

Higher doses of hydrocortisone not linked to neurodevelopmental impairments in low birth weight infants

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News